Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$2.15 USD
-0.07 (-3.15%)
Updated Jun 14, 2024 10:46 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 141 - 160 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
So Far so Good on the Safety Front; Awaiting Activity Roll Out During 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2H19 Value Drivers Within Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of the Expansion Cohort at a Higher Than Anticipated Dose Bodes Well for the Program Going Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1H19 Recap; Looking Forward to XMT-1536 RP2D and Dose-Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
On Track to Pick XMT-1536 Dose, Add to Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ASCO Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1536, It''s Active; Now on to Dose Expansion for a Handle on Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As Anticipated, XMT-1536-Related ASCO Abstract Reflects Immature Data as of January 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Additional 1536 Data in 2Q19 and New Candidate in H2:19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Peer Setback and Augmented Balance Sheet Are an Opportunity; Target Lowered to $7 to Account for Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1522 Discontinued, but Encouraging XMT-1536 Initial Results
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D